nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

04.05.2021 | case report

Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation—evaluation of in vivo sensitivity to imatinib

verfasst von: Olga Kuczkiewicz-Siemion, Agnieszka Dansonka-Mieszkowska, Piotr Rutkowski, Anna Klimczak, Andrzej Tysarowski, Monika Prochorec-Sobieszek, Anna Szumera-Ciećkiewicz

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Summary

Most gastrointestinal stromal tumors (GISTs) are associated with molecular changes in two genes, KIT and platelet-derived growth factor receptor‑α (PDGFRA). However, only 5–10% of GISTs harbor PDGFRA mutation. Most tumors carry substitution affecting codon D842 in exon 18, which entails imatinib resistance. The other substitutions in this codon are extremely rare mutations (only 13 reported cases) involving D842Y substitution. This report presents a case of gastric GIST infiltrating liver segment III in a 70-year-old man. The tumor was studied histologically, immunohistochemically, and genetically. Mutational analysis revealed PDGFRA exon 18 mutation—p.(D842Y), c.2524G > T. Diagnosis of GIST with a high risk of progression was made. Due to subsequent liver metastases, imatinib therapy was commenced, which resulted in a minor disease response at a higher dose of imatinib. Our case is a unique, comprehensive report of in vivo PDGFRA D842Y-mutated GIST partial sensitivity to imatinib.

Vorheriger Artikel Are there still indications for whole brain irradiation in 2021?

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8. https://doi.org/10.1097/00000658-200001000-00008.CrossRefPubMedPubMedCentral

Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259–69.PubMedPubMedCentral

Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg. 1996;33(10):817–72.CrossRef

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83. https://doi.org/10.1053/j.semdp.2006.09.001.CrossRefPubMed

Chetty R, Serra S. Molecular and morphological correlation in gastrointestinal stromal tumours (GISTs): an update and primer. J Clin Pathol. 2016;69(9):754–60. https://doi.org/10.1136/jclinpath-2016-203807.CrossRefPubMed

Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865–78. https://doi.org/10.1038/nrc3143.CrossRefPubMed

Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557–86. https://doi.org/10.1146/annurev.pathmechdis.3.121806.151538.CrossRefPubMed

Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol. 2004;202(4):430–8. https://doi.org/10.1002/path.1546.CrossRefPubMed

Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28(7):889–94. https://doi.org/10.1097/00000478-200407000-00007.CrossRefPubMed

10.

Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest. 2004;84(7):874–83. https://doi.org/10.1038/labinvest.3700122.CrossRefPubMed

11.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–9. https://doi.org/10.1200/jco.2003.04.190.CrossRefPubMed

12.

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360–7. https://doi.org/10.1200/jco.2008.17.4284.CrossRefPubMed

13.

Wozniak A, Rutkowski P, Piskorz A, Ciwoniuk M, Osuch C, Bylina E, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol. 2012;23(2):353–60. https://doi.org/10.1093/annonc/mdr127.CrossRefPubMed

14.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–9. https://doi.org/10.1200/jco.2007.15.7461.CrossRefPubMed

15.

Farag S, Somaiah N, Choi H, Heeres B, Wang WL, van Boven H, et al. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. Eur J Cancer. 2017;76:76–83. https://doi.org/10.1016/j.ejca .2017.02.007.CrossRef

16.

Sun Q, Wu HY, Chen XY, Yang J, Ye Q, Fan XS. Signet-ring epithelioid gastrointestinal stromal tumor with rare D842Y mutation in exon 18 of PDGFRα: report of a case. Zhonghua Bing Li Xue Za Zhi. 2011;40(6):414–5.PubMed

17.

Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357–64. https://doi.org/10.1200/jco.2005.14.068.CrossRefPubMed

18.

Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52–68. https://doi.org/10.1097/01.pas.0000146010.92933.de.CrossRefPubMed

19.

Corless CL. Gastrointestinal stromal tumors: what do we know now? Mod Pathol. 2014;1:1–16. https://doi.org/10.1038/modpathol.2013.173.CrossRef

20.

Liang L, Yan XE, Yin Y, Yun CH. Structural and biochemical studies of the PDGFRA kinase domain. Biochem Biophys Res Commun. 2016;477(4):667–72. https://doi.org/10.1016/j.bbrc.2016.06.117.CrossRefPubMed

21.

Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al. The c‑KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99(5):1741–4. https://doi.org/10.1182/blood.v99.5.1741.CrossRefPubMed

22.

National Comprehensive Cancer Network. Version 1.2021 - October 30, 2020. https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf.

23.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, et al. Association of Dasatinib with progression-free survival among patients with advanced gastrointestinal Stromal tumors resistant to Imatinib. JAMA Oncol. 2018;4(6):814–20. https://doi.org/10.1001/jamaoncol.2018.0601.CrossRefPubMedPubMedCentral

Titel: Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation—evaluation of in vivo sensitivity to imatinib
verfasst von: Olga Kuczkiewicz-Siemion
Agnieszka Dansonka-Mieszkowska
Piotr Rutkowski
Anna Klimczak
Andrzej Tysarowski
Monika Prochorec-Sobieszek
Anna Szumera-Ciećkiewicz
Publikationsdatum: 04.05.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00708-2

Are there still indications for whole brain irradiation in 2021?

Open Access
short review

Malnutrition and cancer, diagnosis and treatment

Open Access
short review

Importance of performance status and physical activity in cancer patients

Open Access
review

Immunotherapy revisited

editorial

WHO classification of tumors of the nervous system: preview of the upcoming 5th edition

Open Access
short review

Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management

review

Springer Medizin Österreich

Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation—evaluation of in vivo sensitivity to imatinib

Summary

Weitere Artikel der Ausgabe 2/2021

Are there still indications for whole brain irradiation in 2021?

Malnutrition and cancer, diagnosis and treatment

Importance of performance status and physical activity in cancer patients

Immunotherapy revisited

WHO classification of tumors of the nervous system: preview of the upcoming 5th edition

Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Are there still indications for whole brain irradiation in 2021?

Malnutrition and cancer, diagnosis and treatment

Importance of performance status and physical activity in cancer patients

Immunotherapy revisited

WHO classification of tumors of the nervous system: preview of the upcoming 5th edition

Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management